Literature DB >> 8191414

Anticoagulant therapy in deep venous thrombosis. A randomized controlled study.

H K Nielsen1, S E Husted, L R Krusell, H Fasting, P Charles, H H Hansen, B O Nielsen, J B Petersen, P Bechgaard.   

Abstract

Ninety patients with venographically proven deep venous thrombosis(DVT) but without clinical signs of pulmonary embolism(PE) were randomized into two different treatment regimens to compare the safety and efficacy of continuous intravenous heparin and oral anticoagulant(AC) treatment versus non-AC treatment. All patients in the two treatment groups were actively mobilized from the day of admission and wore graduated compressing stockings. In the non-AC-group the patients were treated with phenylbutazone for ten days. Treatment with heparin was maintained for 6 days and oral AC treatment was given from the third day and continued for 3 months. Venography was repeated after 30 days. A perfusion-ventilation lung scan was performed on day 1-2, 10 and 60. In fifty-nine patients a revenography was performed, twenty nine in the AC-group and thirty in the non-AC group. For distal veins regression was found in nine and eight respectively (4.4% in favour of AC, 95% confidence limit 27.5% to -18.7%) and in proximal veins regression was found in five and eight, respectively (10.9% in favour of AC, 95% confidence limit 32.0% to -10.1%). No difference in lung scans was found after 10 days (0.8% in favour of AC, 95% confidence limit 21.5% to -19.9%) or after 60 days (3.3% in favour of non-AC treatment, 95% confidence limit 21.8% to -28.5%). In the AC group the incidence of bleeding complications was 8.3%. No side-effects of phenylbutazone was found. The present controlled clinical study demonstrated no effect of AC-treatment on DVT progression in actively mobilized patients wearing graduated compressing stockings when compared to a non-AC treated group receiving analgetic therapy with phenylbutazone. However, the patient population of the study is relatively small with wide confidence intervals for differences between groups. Before more general recommendations can be made, a large scale placebo-controlled study is needed to evaluate the possible effect of AC-treatment in DVT patients, who can be mobilized from the first day.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8191414     DOI: 10.1016/0049-3848(94)90100-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  11 in total

1.  Guidelines for anticoagulation therapy for venous thromboembolism.

Authors:  David K Cundiff
Journal:  J Gen Intern Med       Date:  2002-01       Impact factor: 5.128

2.  Anticoagulants for deep venous thrombosis.

Authors:  D K Cundiff
Journal:  J R Soc Med       Date:  2001-11       Impact factor: 5.344

Review 3.  Anticoagulants versus non-steroidal anti-inflammatories or placebo for treatment of venous thromboembolism.

Authors:  D K Cundiff; J Manyemba; J C Pezzullo
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

4.  Evidence-based medicine and the Cochrane Collaboration on trial.

Authors:  David K Cundiff
Journal:  MedGenMed       Date:  2007-06-12

Review 5.  A systematic review of Cochrane anticoagulation reviews.

Authors:  David Keith Cundiff
Journal:  Medscape J Med       Date:  2009-01-06

Review 6.  Anticoagulation therapy for venous thromboembolism.

Authors:  David K Cundiff
Journal:  MedGenMed       Date:  2004-09-09

Review 7.  Antiplatelet agents for the treatment of deep venous thrombosis.

Authors:  Carolina Dq Flumignan; Luis Cu Nakano; Jose Cc Baptista-Silva; Ronald Lg Flumignan
Journal:  Cochrane Database Syst Rev       Date:  2022-07-25

Review 8.  Diet as prophylaxis and treatment for venous thromboembolism?

Authors:  David K Cundiff; Paul S Agutter; P Colm Malone; John C Pezzullo
Journal:  Theor Biol Med Model       Date:  2010-08-11       Impact factor: 2.432

9.  Treatment of distal deep vein thrombosis.

Authors:  George Kirkilesis; Stavros K Kakkos; Colin Bicknell; Safa Salim; Kyriaki Kakavia
Journal:  Cochrane Database Syst Rev       Date:  2020-04-09

Review 10.  Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis.

Authors:  Petra M G Erkens; Hugo ten Cate; Harry R Büller; Martin H Prins
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.